# 1. Financial Performance ## A. Key Figures * **Consolidated Revenue (Q2 FY'26):** **₹2,164 Cr** · **H1 FY'26 Revenue:** **₹4,278 Cr** (vs. ₹4,307 Cr prior) * **EBITDA (H1 FY'26):** **₹603 Cr** (vs. ₹738 Cr prior) · **Q2 EBITDA:** **₹278 Cr** * **PAT (Q2 FY'26):** **₹62 Cr** · **PBT (Q2 FY'26):** **₹78 Cr** * **Carbon Black Volume (H1 FY'26):** **315,821 MT** (+4% YoY) * **Aquapharm Revenue (Q2 FY'26):** **₹395 Cr** (+9% YoY) · **EBITDA:** **₹48 Cr** * **Gross Debt Reduction:** **>₹300 Cr** since Mar-25 * **Working Capital Cash Release (H1 FY'26):** **~₹240 Cr** (12-day improvement) ## B. Revenue & Profit * **Resilient Volume Growth:** Carbon black sales volumes rose **4% YoY** despite flat H1 revenues, indicating pricing or mix headwinds. * **Aquapharm Strength:** Business delivered **9% top-line growth** and robust EBITDA, showcasing operational improvement and market traction. * **Cost Inflation:** Employee expenses rose **25% YoY** due to appraisals, hiring, and expansion, with a **non-recurring ₹2–3 Cr** bonus component. * **Stable Realizations:** Management expects **no significant change in net realization** near term despite evolving product mix. ## C. EBITDA Trends * **Margin Pressure Persists:** H1 EBITDA declined YoY despite volume growth, with **EBITDA/ton down ₹4,000 to ₹16,000**, reflecting cost and mix challenges. * **Aquapharm Margin Recovery:** EBITDA improved sequentially to **₹33 Cr in Q2 from ₹28 Cr in Q1**, driven by better mix and cost control. * **EBITDA Outlook:** Company projects **₹75 Cr EBITDA for the nine-month global business**, implying improvement in second half. ## D. Balance Sheet * **Deleveraging Momentum:** **Over ₹300 Cr gross debt reduction** since March 2025 highlights strong cash flow and disciplined financial management. * **Strategic Positioning:** PCBL Chemical maintains **strong global ESG credentials and brand equity**, focused on high-margin segments and integrated operations. ## E. Cash Flow * **Working Capital Optimization:** **12-day reduction in working capital cycle** released **~₹240 Cr**, supporting cash flow strength. * **Operational Efficiency:** Carbon black plants running at **>99% capacity utilization**, with expectations of further performance gains and **sustained healthy cash generation** underpinning dividends. --- # 2. Volume & Segment Growth ## A. Key Figures * **Carbon Black Sales Volume:** **161,728 tons** total (+6% YoY) · **99,549 tons** domestic · **62,179 tons** international * **Power Generation:** **223 MUs** (+7% YoY) · **External Sales:** **138 MUs** (+10% YoY) * **H1 Power Growth:** **+9% generation** · **+11% sales volume** (YoY) * **Carbon Black EBITDA per Ton:** **₹16,000** (H1 FY'26) * **Aquapharm EBITDA:** **₹50 Cr** current run rate · **target ₹75 Cr** by FY'26 end * **Home Care QoQ Growth:** **+18% volume** · **Water Solutions +16% QoQ** ## B. Carbon Black & Power Performance * **Resilient Volume Growth:** Carbon black volumes rose **6% YoY** despite global pricing pressures and softer demand, reflecting strong market positioning and operational execution. * **Specialty Black Momentum:** Specialty carbon black volumes show **strong quarter-on-quarter and year-on-year growth**, with increasing share expected; driven by supply chain resilience and expanding applications. * **Power Generation Strength:** Power output and external sales grew **7% and 10% YoY**, respectively, signaling efficient captive utilization and rising third-party demand. * **Margin Recovery Underway:** Despite current EBITDA per ton below historical norms, **₹16,000/ton** reflects improvement from prior lows, aided by stabilized crude oil prices (~$60–62). ## C. Home Care & Water Solutions Growth * **Strong Consumer-Led Uptick:** Home Care and Water Solutions delivered **double-digit QoQ volume growth**, fueled by deepening partnerships with **P&G and Unilever** and tailwinds from smart appliances and regulatory shifts (EVPA phase-out). * **Segment Divergence:** While Home Care (~10,000 tons) and Water (~5,000 tons) grew, **Application-Specific Solutions stagnated** due to textile sector weakness, and **Oil & Gas volumes declined**. ## D. Oil & Gas Downturn * **Sharp U.S. Volume Drop:** Oil & Gas segment saw a **40% volume decline** in the U.S., driven by cyclical weakness and suboptimal oil prices (WTI $62–65 vs. ideal $75–80), suppressing demand for efficiency chemicals. * **Cyclical Sensitivity Confirmed:** Management reaffirms that U.S. performance is tightly linked to oil price recovery, with EBITDA currently flat due to this exposure. ## E. Aquapharm Advancement * **Margin Expansion via Mix Shift:** Aquapharm’s specialty segment achieved a **10% improvement in gross margins**, supported by favorable product mix. * **Full Green Chelate Portfolio Commercialized:** Now the **only player with full GLDA, MGDA, and IDS coverage**, positioning Aquapharm as a leader in sustainable chelates. * **EBITDA Ramp-Up in Progress:** On track to reach **₹75 Cr exit run rate**, up from current **₹50 Cr**, driven by scale and product leadership. --- # 3. Product & Innovation ## A. Battery Materials Tech * **Technology Leadership:** PCBL Chemical now the **first global player** with full suite of advanced conductive materials—superconductive carbon black, nano-silicon, and acetylene black—enabling leadership in next-gen battery solutions. * **Strong Market Validation:** Lab-scale samples shared with multiple global battery players have generated significant interest, reinforcing commercial potential. --- # 4. Capacity & Utilization ## A. Key Figures * **Carbon Black Sales Volume:** **161,728 MT** consolidated (+5% QoQ) * **Capacity Utilization:** **>99%** consolidated carbon black (Q2 FY'26) ## B. Plant Commissioning * **New Specialty Lines Onstream:** Commissioning of **1,000 MTPA super conductive black line in Palej** and **90,000 MTPA rubber line in Tamil Nadu** nearing completion, with commercial production starting imminently. * **Mundra & Acetylene Black Progress:** **20,000 MTPA Specialty Black Line in Mundra** preponed to March 2026; **4,000 MTPA acetylene black plant** to be commissioned within 18 months. * **Vertical Integration Achieved:** **PBTC manufacturing plant now operational**, shifting from traded to in-house supply, with sampling underway for global water treatment clients. * **Pilot Plant Catalyst:** **Nano silicon customer approvals pending**; timeline hinges on pilot plant commissioning expected in 2–3 months. ## C. Expansion Projects * **Phased Growth Pipeline:** **Multiple strategic projects across PCBL Chemicals** set to ramp over 18 months, including new lines in Mundra, Palej, and Nanovace pilot plant, reinforcing long-term scale-up. ## D. Capacity Utilization * **Near-Full Operational Leverage:** Sustained **>99% utilization** despite constraints, reflecting robust demand and efficient operations. * **De-bottlenecking Success:** **Acetyl chloride line constraints resolved**, enhancing output flexibility; granulation infrastructure added to support new product forms. * **Future Run-Rate Target:** Company targets **over 50% utilization next fiscal**, ramping to **full 100% run-rate by year-end**, aligned with new capacity absorption. ## E. Brownfield Growth * **Strategic Optimization Underway:** **Acetyl chloride capacity to more than double** via de-bottlenecking (4 → ~300,000 tons); **non-viable plants in US, Europe, and South Africa to close** as part of footprint rationalization. --- # 5. Export & Geography Mix ## A. Key Figures * **US Volume Exposure:** **~5%** of total carbon black sales (~30,000 tons) * **US Revenue Exposure:** **~₹350 Cr** from US exports, representing **9% of total revenue** * **US Import Market Size:** **~200,000 tons/year** of carbon black imported, indicating significant runway ## B. US Market Exposure * **Tariff Resilience:** Despite a **50% tariff** and near-term softness from low WTI prices, the US remains import-dependent, supporting long-term volume and margin recovery. * **Strategic Positioning:** Local manufacturing in Houston provides a competitive edge in the oil & gas segment, particularly in the Permian Basin, insulating from Chinese competition. * **Operational Improvement:** Sales momentum resumed in **August–September**, with enhanced technical sales teams building resilience for future growth. * **Diversified Supply Chain:** India-manufactured products serve Europe (80%) and US (20%), minimizing tariff impact while enabling participation in key tenders (e.g., Procter & Gamble). ## C. EU & MEA Sales * **High-Value Market Focus:** Europe is a core high-value market, with the company replicating its successful EU commercial model—strong distribution, technical support, and warehousing—across MEA and the Americas. * **Distribution Expansion:** New partnerships, including **Solevo in Africa** and distributors in Latin America, are expanding regional reach and customer access. ## D. Regional Strategy * **Global Growth Tailwinds:** Conductive carbon black demand is rising globally, driven by electrification, EVs, energy storage, and data centers, with PCBL targeting leadership in key growth corridors. * **Market Rebalancing:** Strategy includes rerouting supply to higher-margin markets and reducing domestic sales to protect margins, with full optimization expected over **a few quarters**. * **Regional Localization Goal:** Aiming to establish PCBL as a local player in each region, maintaining dominance in India and expanding into ASEAN, China, and EU. --- # 6. Risks & Trade Factors ## A. Key Figures * **Carbon Black EBITDA Impact:** **₹70 Cr** annualized (from 20% effective tariff) · **2,000 Tons** volume reduction due to US tariffs * **Crude Oil Price:** **$63–64/bbl** (Jul–Sep) vs. $72–73/bbl prior quarter * **Russian Imports:** **8,000–10,000 Tons/month** into India, pressuring spot prices ## B. US Tariff Pressure * **Sharp Margin Pressure:** Carbon black margins compressed by **20% effective US tariff rate**, driven by 40% of export value subject to 50% duty on non-US raw materials. * **Volume & Timing Impact:** Export volumes reduced by **~2,000 tons** in the quarter; tariff-related delays pushed recovery target to **Q4 of current fiscal year**. * **Strategic Offset:** Home Care and Aquapharm businesses poised to gain from **US 100% tariffs on Chinese goods**, enabling India-based supply to capture diverted demand. ## C. Input Cost Volatility * **Downstream Pricing Pressure:** Significant crude oil price decline led to aggressive spot-market competition, forcing pricing alignment to maintain **full capacity utilization**. ## D. Competitive Pricing * **Oversupply & Soft Demand:** Market oversupply, fueled by **Russian imports** and **deferred auto purchases**, intensified pricing pressure despite stable domestic volumes. * **Margin Resilience Focus:** No inventory losses reported; margin compression attributed entirely to **competitive pricing dynamics**, with cross-functional teams driving cost optimization. ## E. Geopolitical Impact * **Diversification Opportunity:** Geopolitical shifts, particularly **US-China trade decoupling**, are creating sourcing opportunities for Aquapharm’s specialty chemicals in North America. --- # 7. Guidance & Outlook ## A. Key Figures * **EBITDA Target:** **₹75 Cr** quarterly run rate by end of Q4 * **Nano Silicon Capex:** **₹500 Cr** investment targeting **₹1,200 Cr EBITDA by 2030** ## B. EBITDA Run Rate * **Clear Path to EBITDA Ramp-Up:** Improvement expected from Q3 onward, driven by completed operational initiatives, new product launches, and a major RO/purification plant contract with Saudi Water Authorities. * **Operating Leverage Tied to Oil Prices:** EBITDA momentum to strengthen as WTI rises above $75–$80, boosting demand for premium chemical solutions, though relationship is non-linear. * **Confidence in Long-Term Targets:** Management reaffirms unchanged long-term guidance, citing internal execution and recovery trajectory despite near-term volatility. ## C. Margin Recovery * **Two-Year Margin Recovery Plan:** Carbon black and Aquapharm margins expected to normalize as raw material stability and improved product mix take effect. * **Performance Levers in Motion:** Ongoing focus on operating leverage, yield optimization, and efficiency gains to support margin expansion. ## D. Demand Projections * **Domestic Auto Recovery Underway:** GST cut has spurred demand rebound, with domestic tyre demand projected to grow **6–8% in FY26**, led by replacement cycle strength. * **Global Tyre Capex Signals Confidence:** Major players investing ~$4B in North America through 2029, underscoring resilient long-term demand fundamentals despite short-term headwinds. * **Near-Term Challenges Transitory:** Tariff impacts, post-GST purchase deferrals, and soft sentiment seen as temporary; company believes it has hit a cyclical low. * **Pipeline Momentum Building:** Product approvals expected within 6–9 months, with commercial ramp-up anticipated in H2 of next year. ## E. Capex Plans * **Strategic Bet on Nano Silicon:** ₹500 Cr investment reflects long-term positioning in high-growth technology, with a clear roadmap to ₹1,200 Cr EBITDA by 2030. * **Resilient Outlook Amid Volatility:** Company maintains confidence in strategy and execution, expecting stabilization and growth in coming quarters.